资讯
Investigators compared risk prediction using PathomIQ's platform to molecular test results, evaluating its ability to predict biochemical recurrence in high-risk patients.
Health Canada has allowed the firm to bypass a requirement that tests be authorized for non-professional use prior to self-test authorization.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果